FDA Approved: ROZLYTREK — Original Application (Genentech, Inc.)

View source ↗

Summary

Rozlytrek (entrectinib) received FDA approval in an original application for the treatment of NTRK gene fusion-positive solid tumors and ROS1-positive non-small…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ntrk Gene Fusion-positive Solid Tumors
• Ros1-positive Non-small Cell Lung Cancer

Drugs mentioned

• Rozlytrek (entrectinib)

Snippet

ORIG AP for ROZLYTREK (ENTRECTINIB)